REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.4B-9.2% YoY

Gross Profit

$1.1B83.7% margin

Operating Income

$480M35.0% margin

Net Income

$461M33.6% margin

EPS (Diluted)

$3.99

QoQ Revenue Growth

-28.8%

Cash Flow

Operating Cash Flow

$897M

Free Cash Flow

$823M

Stock-Based Comp.

$108M

Balance Sheet

Total Assets

$12.9B

Total Liabilities

$3.4B

Stockholders' Equity

$9.4B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$1.5B	-9.2%
Gross Profit	$1.1B	$1.4B	-15.5%
Operating Income	$480M	$567M	-15.4%
Net Income	$461M	$478M	-3.5%

Revenue Segments

Product

$1.1B100%

REGN Q1 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena